Vignesh N Hariharan, Minwook Shin, Ching-Wen Chang, Daniel O'Reilly, Annabelle Biscans, Ken Yamada, Zhiru Guo, Mohan Somasundaran, Qi Tang, Kathryn Monopoli, Pranathi Meda Krishnamurthy, Gitali Devi, Nicholas McHugh, David A Cooper, Dimas Echeverria, John Cruz, Io Long Chan, Ping Liu, Sun-Young Lim, Jill McConnell, Satya Prakash Singh, Samuel Hildebrand, Jacquelyn Sousa, Sarah M Davis, Zachary Kennedy, Chantal Ferguson, Bruno M D C Godinho, Yann Thillier, Jillian Caiazzi, Socheata Ly, Manish Muhuri, Karen Kelly, Fiachra Humphries, Alyssa Cousineau, Krishna Mohan Parsi, Qi Li, Yang Wang, René Maehr, Guangping Gao, Dmitry Korkin, William M McDougall, Robert W Finberg, Katherine A Fitzgerald, Jennifer P Wang, Jonathan K Watts, Anastasia Khvorova
The continuous evolution of SARS-CoV-2 variants complicates efforts to combat the ongoing pandemic, underscoring the need for a dynamic platform for the rapid development of pan-viral variant therapeutics. Oligonucleotide therapeutics are enhancing the treatment of numerous diseases with unprecedented potency, duration of effect, and safety. Through the systematic screening of hundreds of oligonucleotide sequences, we identified fully chemically stabilized siRNAs and ASOs that target regions of the SARS-CoV-2 genome conserved in all variants of concern, including delta and omicron...
March 14, 2023: Proceedings of the National Academy of Sciences of the United States of America